GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (OTCPK:CLVSQ) » Definitions » Goodwill-to-Asset

Clovis Oncology (Clovis Oncology) Goodwill-to-Asset : 0.18 (As of Sep. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Clovis Oncology Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Clovis Oncology's Goodwill for the quarter that ended in Sep. 2022 was $63.1 Mil. Clovis Oncology's Total Assets for the quarter that ended in Sep. 2022 was $346.8 Mil. Therefore, Clovis Oncology's Goodwill to Asset Ratio for the quarter that ended in Sep. 2022 was 0.18.


Clovis Oncology Goodwill-to-Asset Historical Data

The historical data trend for Clovis Oncology's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clovis Oncology Goodwill-to-Asset Chart

Clovis Oncology Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.07 0.09 0.10 0.13

Clovis Oncology Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.13 0.14 0.16 0.18

Competitive Comparison of Clovis Oncology's Goodwill-to-Asset

For the Biotechnology subindustry, Clovis Oncology's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clovis Oncology's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clovis Oncology's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Clovis Oncology's Goodwill-to-Asset falls into.



Clovis Oncology Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Clovis Oncology's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Goodwill to Asset (A: Dec. 2021 )=Goodwill/Total Assets
=63.07/472.833
=0.13

Clovis Oncology's Goodwill to Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

Goodwill to Asset (Q: Sep. 2022 )=Goodwill/Total Assets
=63.07/346.775
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clovis Oncology  (OTCPK:CLVSQ) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Clovis Oncology Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Clovis Oncology (Clovis Oncology) Business Description

Traded in Other Exchanges
N/A
Address
5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
Executives
Thomas C. Harding officer: See Remarks 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Gillian C Ivers-read officer: See Remarks C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Lindsey Rolfe officer: See remarks C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Daniel W Muehl officer: See remarks 5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862
Paul Edward Gross officer: See Remarks 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302
Ronit Simantov director 1988 CHAPEL STREET, NEW HAVEN CT 06515
James C Blair director 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Patrick J Mahaffy director, officer: President and CEO C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Thorlef Spickschen director TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000
Richard A. Fair director C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Hooks Corwin Dale officer: See remarks C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301
Paul H Klingenstein director 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
Ginger L Graham director AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

Clovis Oncology (Clovis Oncology) Headlines

From GuruFocus